Form 4: ICU Medical CEO Vivek Jain Reports Stock Transactions Following Vesting of Restricted Stock Units
SEC Form 4
ICU Medical's CEO, Vivek Jain, reports the acquisition and disposal of common stock following the vesting of restricted stock units and performance-based restricted stock units.
Summary
- Vivek Jain, CEO of ICU Medical, reported transactions involving the company's common stock on March 7th and 8th, 2024.
- These transactions involved the acquisition of shares through the vesting of Restricted Stock Units (RSUs) and Performance-based Restricted Stock Units (PRSUs).
- The vesting of PRSUs was approved by the Compensation Committee in February 2024.
- Mr. Jain disposed of shares to cover tax obligations related to the vesting of these units.
- On March 7th, 3,218 RSUs and 19,306 PRSUs vested, while on March 8th, 2,525 RSUs and 8,331 PRSUs vested.
- The disposal prices for the shares were $105.39 on March 7th and $104.52 on March 8th.
- Following these transactions, Mr. Jain directly owns 102,393 shares of common stock and indirectly owns 88,698 shares through a trust.
Sentiment
Score: 6
Explanation: The sentiment is neutral as the document primarily reports routine stock transactions related to executive compensation. The vesting of performance-based units suggests positive performance, but the subsequent sale is a standard practice for tax obligations.
Positives
- The vesting of RSUs and PRSUs indicates that Mr. Jain has met certain performance criteria or time-based requirements set by the company.
- The Compensation Committee's approval of the PRSU vesting suggests confidence in the company's performance.
Industry Context
Form 4 filings are a routine part of executive compensation and provide transparency into insider transactions. The vesting of RSUs and PRSUs is a common practice to incentivize and retain key executives.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders.
- The vesting of performance-based units could indirectly signal positive company performance to shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/08/2021 | Date of grant for PRSUs that had a 3-Year cliff-vest subject to the satisfaction of performance-based metrics and continuous services through the vest date. |
| 03/07/2022 | Date of grant for PRSUs that had a 2-year cliff-vest performance period subject to the satisfaction of performance-based metrics and continuous services through the vest date. |
| February 2024 | Compensation Committee approved vesting of PRSUs. |
| 03/07/2024 | Transaction date for RSU and PRSU vesting and stock disposal. |
| 03/08/2024 | Transaction date for RSU and PRSU vesting and stock disposal. |
| 03/11/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.